Amanda Jones, PharmD
Axsome Therapeutics, Inc, New York, New York; Corresponding author: Amanda Jones, PharmD, Axsome Therapeutics, 22 Cortland St, New York, NY 10007 ([email protected]).
Original Research
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
May 30, 2022
Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...
